Monday, January 18, 2021
Home Latest Pharma-News Eisai and Wren Therapeutics Enter Into Research Collaboration Agreement for Drug Discovery...

Eisai and Wren Therapeutics Enter Into Research Collaboration Agreement for Drug Discovery for Synucleinopathies

November 30, 2020: Eisai and Wren Therapeutics announced that the companies have entered into an exclusive research collaboration agreement aiming to advance the discovery of novel small molecules that target α-synuclein for the potential treatment of synucleinopathies including Parkinson’s disease and dementia with Lewy bodies.

Wren possesses a novel network kinetics drug discovery platform that precisely quantifies the effects of small molecules on the protein misfolding and aggregation pathway that causes neurodegenerative diseases.

- Advertisement -

Wren’s approach to synucleinopathies is focused on identifying novel small molecules that selectively control the aggregation process of α-synuclein, which is associated with the onset and progression of these diseases.

The collaboration will use Wren’s network kinetics drug discovery platform, alongside Eisai’s extensive experience in drug discovery for neurodegenerative disorders, to accelerate the development of clinical candidates.

https://www.wrentherapeutics.com/news/Wren-Eisai-research-collaboration/

LEAVE A REPLY

Please enter your comment!
Please enter your name here

eighteen + 1 =

Most Popular

GSK presents positive efficacy data of dostarlimab at ASCO Gastrointestinal Cancers Symposium

January 16, 2021: "GlaxoSmithKline (GSK) plc announced updated data from GARNET cohort F evaluating dostarlimab in mismatch repair-deficient (dMMR) non-endometrial advanced solid...

Bharat Biotech signs agreement with Precisa Medicamentos for supply of ‘COVAXIN™’ to Brazil

January 12, 2020: "Bharat Biotech announced that it has signed an agreement with Precisa Medicamentos for the supplies of COVAXIN™ to Brazil.

What Is a Blockbuster Drug?

What Is a Blockbuster Drug? "Blockbuster drugs are those that generate at least $1 billion of revenue per...

Boehringer Ingelheim and Enara Bio join forces to discover Cancer Immunotherapies

January 12th, 2021: Boehringer Ingelheim and Enara Bio announced that they have entered into a strategic collaboration and licensing agreement to research...